[Anti-angiogenic therapy in ocular disease--current and future strategies].
Originating from therapeutic concepts in oncology, angioinhibitory strategies have changed the way ophthalmological patients are treated for a variety of diseases like age-related macular degeneration, diabetic retinopathy or retinal vein occlusion. It is likely that these therapeutic options will not be limited to retinal disease, but will also prove useful for corneal disorders associated with lymph- or angiogenesis. This review is intended to provide a concise overview of the current options investigated in clinical trials.
Agostini
H
H
Universitäts-Augenklinik Freiburg. hansjuergen.agostini@uniklinik-freiburg.de
Feltgen
N
N
Hansen
L
L
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000639:trends*; D005128:Eye Diseases / Q000188:drug therapy* / Q000517:prevention & control*; D005544:Forecasting; D005858:Germany; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000517:prevention & control*; D010818:Practice Patterns, Physicians' / Q000639:trends*
D020533:Angiogenesis Inhibitors